COLL
Price
$31.02
Change
+$0.54 (+1.77%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
987.93M
57 days until earnings call
Intraday BUY SELL Signals
LFCR
Price
$5.67
Change
+$0.22 (+4.04%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
181.92M
58 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

COLL vs LFCR

Header iconCOLL vs LFCR Comparison
Open Charts COLL vs LFCRBanner chart's image
COLL vs LFCR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
COLL vs. LFCR commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a StrongBuy and LFCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2026
Stock price -- (COLL: $30.46 vs. LFCR: $5.45)
Brand notoriety: COLL and LFCR are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: COLL: 139% vs. LFCR: 130%
Market capitalization -- COLL: $987.93M vs. LFCR: $181.92M
COLL [@Pharmaceuticals: Generic] is valued at $987.93M. LFCR’s [@Pharmaceuticals: Generic] market capitalization is $181.92M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COLL’s FA Score shows that 0 FA rating(s) are green whileLFCR’s FA Score has 1 green FA rating(s).

  • COLL’s FA Score: 0 green, 5 red.
  • LFCR’s FA Score: 1 green, 4 red.
According to our system of comparison, COLL is a better buy in the long-term than LFCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COLL’s TA Score shows that 5 TA indicator(s) are bullish while LFCR’s TA Score has 5 bullish TA indicator(s).

  • COLL’s TA Score: 5 bullish, 5 bearish.
  • LFCR’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, LFCR is a better buy in the short-term than COLL.

Price Growth

COLL (@Pharmaceuticals: Generic) experienced а -9.83% price change this week, while LFCR (@Pharmaceuticals: Generic) price change was +13.54% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.16%. For the same industry, the average monthly price growth was +24.29%, and the average quarterly price growth was +16.47%.

Reported Earning Dates

COLL is expected to report earnings on Jul 30, 2026.

LFCR is expected to report earnings on Jul 31, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-2.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COLL($988M) has a higher market cap than LFCR($182M). LFCR has higher P/E ratio than COLL: LFCR (51.23) vs COLL (14.79). LFCR (-33.374) and COLL (-34.212) have similar YTD gains . COLL has higher annual earnings (EBITDA): 411M vs. LFCR (-8.81M). COLL has more cash in the bank: 422M vs. LFCR (20.8M). LFCR has less debt than COLL: LFCR (149M) vs COLL (808M). COLL has higher revenues than LFCR: COLL (796M) vs LFCR (129M).
COLLLFCRCOLL / LFCR
Capitalization988M182M543%
EBITDA411M-8.81M-4,664%
Gain YTD-34.212-33.374103%
P/E Ratio14.7951.2329%
Revenue796M129M617%
Total Cash422M20.8M2,029%
Total Debt808M149M542%
FUNDAMENTALS RATINGS
COLL vs LFCR: Fundamental Ratings
COLL
LFCR
OUTLOOK RATING
1..100
6026
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
88
Overvalued
PROFIT vs RISK RATING
1..100
73100
SMR RATING
1..100
35100
PRICE GROWTH RATING
1..100
6483
P/E GROWTH RATING
1..100
876
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COLL's Valuation (53) in the Pharmaceuticals Other industry is somewhat better than the same rating for LFCR (88) in the Industrial Specialties industry. This means that COLL’s stock grew somewhat faster than LFCR’s over the last 12 months.

COLL's Profit vs Risk Rating (73) in the Pharmaceuticals Other industry is in the same range as LFCR (100) in the Industrial Specialties industry. This means that COLL’s stock grew similarly to LFCR’s over the last 12 months.

COLL's SMR Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for LFCR (100) in the Industrial Specialties industry. This means that COLL’s stock grew somewhat faster than LFCR’s over the last 12 months.

COLL's Price Growth Rating (64) in the Pharmaceuticals Other industry is in the same range as LFCR (83) in the Industrial Specialties industry. This means that COLL’s stock grew similarly to LFCR’s over the last 12 months.

LFCR's P/E Growth Rating (6) in the Industrial Specialties industry is significantly better than the same rating for COLL (87) in the Pharmaceuticals Other industry. This means that LFCR’s stock grew significantly faster than COLL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COLLLFCR
RSI
ODDS (%)
Bullish Trend 2 days ago
75%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
65%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 14 days ago
70%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 9 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
COLL
Daily Signal:
Gain/Loss:
LFCR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRIEX13.85N/A
N/A
Meridian Hedged Equity Investor
STCIX10.97N/A
N/A
Virtus Silvant Large-Cap Growth Stk A
CLSPX33.58N/A
N/A
Columbia Select Mid Cap Gro Fd I
LMGAX31.06N/A
N/A
Lord Abbett Growth Opportunities A
TEDRX30.67N/A
N/A
Franklin Mutual Global Discovery R

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with AMPH. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then AMPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
-4.15%
AMPH - COLL
42%
Loosely correlated
+0.22%
AMRX - COLL
40%
Loosely correlated
-1.94%
VTRS - COLL
37%
Loosely correlated
-0.76%
EBS - COLL
37%
Loosely correlated
-3.30%
ANIP - COLL
34%
Loosely correlated
-2.69%
More

LFCR and

Correlation & Price change

A.I.dvisor tells us that LFCR and SHPH have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LFCR and SHPH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LFCR
1D Price
Change %
LFCR100%
+12.37%
SHPH - LFCR
31%
Poorly correlated
-1.43%
NBIX - LFCR
29%
Poorly correlated
-3.81%
HLN - LFCR
28%
Poorly correlated
-1.58%
COLL - LFCR
28%
Poorly correlated
-4.15%
PAHC - LFCR
27%
Poorly correlated
-4.60%
More